Life sciences investment analysis
Evaluating the attractiveness of investment opportunities in the life sciences—whether individual assets, multifaceted portfolios or entire companies—is a complex exercise that requires both instinct and precision: the instinct to recognize the scientific and clinical promise of an asset, envision the path to market, and anticipate the perceptions of customers, payers and end-users; the investment-grade precision to forecast commercial potential and support a clear decision.
Integrating depth in business, science and healthcare, Shift Health brings discerning instinct and data-driven precision to opportunity assessment. Our track record evaluating a spectrum of investment scenarios, therapy areas and asset classes across diverse and increasingly convergent sectors allows us to apply proven analytical frameworks that separate signals from the noise. We are adept at translating relevant evidence into dynamic and multivariate financial models that support sound valuations our clients can trust.
Opportunity Identification — Opportunity Evaluation — Financial Modeling
A large institutional investment firm engaged Shift Health to evaluate the products in a portfolio of pharma royalties it had an opportunity to acquire.
A US-based biotech company required support to identify, evaluate and prioritize novel immunotherapies and targeted oncology drug candidates to supplement its clinical pipeline.
An Asian specialty healthcare company needed to assess the US market for novel image guidance medical device systems for minimally invasive cardiac interventions.
A top-5 global biopharmaceutical company wanted to identify promising oncology drug candidates that it could in-license or acquire to bolster its oncology franchise revenues over the near term.
Shift Health was engaged by a leading US investment firm to evaluate an asset and project sales in order to inform their decision to invest in an established biotechnology company expanding into new markets.